Does Lurbinectedin Cause Low White Blood Cell Counts?
Yes, lurbinectedin (branded as Zepzelca) commonly causes neutropenia, a drop in neutrophils—a key type of white blood cell—due to its mechanism as a DNA-binding chemotherapy agent that targets rapidly dividing cells, including bone marrow precursors.[1][2]
How Common Is Neutropenia with Lurbinectedin?
In clinical trials for metastatic small cell lung cancer, neutropenia occurred in 66% of patients, with severe (Grade 3/4) cases in 33%. Overall low white blood cell counts (leukopenia) affected 79%, including 35% severe. These rates held across monotherapy and combination use.[1][3]
Why Does It Happen and When?
Lurbinectedin traps topoisomerase I in DNA, halting replication and transcription, which hits hematopoietic stem cells hardest during active production. Drops typically peak 7-14 days post-infusion, with recovery by day 21 in most cycles. Risk rises with prior myelosuppression or combo therapies like doxorubicin.[2][4]
What Do Doctors Do About Low Counts?
Guidelines recommend monitoring complete blood counts weekly for the first two cycles, then before each dose. Hold treatment for absolute neutrophil count below 1.5 × 10^9/L or platelets under 100 × 10^9/L; growth factors like G-CSF prevent or treat severe cases. Infections signal urgent intervention.[1][5]
How Does This Compare to Similar Drugs?
Lurbinectedin neutropenia rates exceed topotecan (50-60% severe) but match other platinum combos in small cell lung cancer. Unlike immunotherapy (e.g., PD-1 inhibitors with <5% severe neutropenia), it's a hallmark of cytotoxic chemo.[3][6]
Patient Risks and Real-World Reports
Severe neutropenia raises infection risk, with 25% of patients experiencing febrile neutropenia. FDA warnings highlight fatal sepsis cases. Patients report fatigue and fever; long-term use may delay marrow recovery.[1][7]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Lurbinectedin Mechanism - NEJM
[3]: IMagine-133 Trial Data - Lancet Oncology
[4]: ASCO Guidelines on Neutropenia
[5]: NCCN Small Cell Lung Cancer Guidelines
[6]: Topotecan vs Lurbinectedin Meta-Analysis - JTO
[7]: FAERS Adverse Event Database (FDA)